Onyx Shifts Priorities Away From JAK Inhibitors, Puts More Emphasis on Carfilzomib
This article was originally published in The Pink Sheet Daily
Executive Summary
Onyx Pharmaceuticals opted out of a licensing agreement with Singapore's S*Bio for JAK2 inhibitors, while shifting more of its focus to proteasome inhibitor carfilzomib.